Cannoli: MANF is a pre-clinical drug. That is why
Post# of 30028
Posted On: 11/23/2014 2:15:12 AM
Cannoli: MANF is a pre-clinical drug. That is why I've never allowed myself to get all gaga about it. I've been in other stocks whose shareholders were enamored with their portfolio's favorite drugs as well. I've seen those drugs fail and the company crashed. (Neopharm)
I think managements efforts to diversify with Elto and ESS is wise. However, Lympro is the only promise of near term revenue. If that revenue doesn't materialize, 2015 may not be too much different than 2014.
My advise? Keep your head in the game, "looking under the hood," instead of becoming complacent and just assuming we'll be the next AMGEN. Here this shareholder nelito was posting a recent exchange he had with Urano that indicated Urano was trying to go another direction than AMBS' MANF patent, but I doubt he realized that. He just saw the word MANF and went Gaga! This is why you need to stick your head under the hood rather than in the sand.... so you can see what is actually going on!
I'm not selling now, I'll wait to see how management executes in the next 2 months and where that puts us.
I think managements efforts to diversify with Elto and ESS is wise. However, Lympro is the only promise of near term revenue. If that revenue doesn't materialize, 2015 may not be too much different than 2014.
My advise? Keep your head in the game, "looking under the hood," instead of becoming complacent and just assuming we'll be the next AMGEN. Here this shareholder nelito was posting a recent exchange he had with Urano that indicated Urano was trying to go another direction than AMBS' MANF patent, but I doubt he realized that. He just saw the word MANF and went Gaga! This is why you need to stick your head under the hood rather than in the sand.... so you can see what is actually going on!
I'm not selling now, I'll wait to see how management executes in the next 2 months and where that puts us.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼